KU Leuven

Postdoctoral project: Design, formulation and evaluation of fixed dose combinations of anti-tuberculosis pharmacotherapy

2024-06-14 (Europe/Brussels)
Baan opslaan

Over de werkgever

KU Leuven is an autonomous university. It was founded in 1425. It was born of and has grown within the Catholic tradition.

De pagina van de werkgever bekijken

The work will be performed in the Drug Delivery and Disposition research group (Department of Pharmaceutical and Pharmacological Sciences; KU Leuven) under the direct supervision of Prof. G. Van den Mooter (https://www.kuleuven.be/wieiswie/nl/person/00006817) in close collaboration with Johnson & Johnson Innovative Medicine.
KU Leuven is one of the top 50 universities in the world according to the "Times Higher Education" ranking, and declared #1 in Most Innovative University of Europe by Reuters 4 years in a row. KU Leuven offers an exciting multi-disciplinary research environment, a broad range of training courses, and full social and medical insurance.
Website unit

Responsibilities

Multidrug resistant tuberculosis (MDR-TB) forms a global threat to public health, with 10 million new cases of TB in 2021, reversing several years of slow decline, partly caused by disruptions in essential treatments during COVID-19 pandemic. About 5% of the patients are infected with MDR-TB, with an estimated 450.000 incident cases in 2021. MDR-TB is a form of TB resistant to at least two of most potent first-line anti-TB drugs, isoniazid, and rifampin. Treating MDR-TB is complex and challenging, requiring daily oral administration of 3 to 4 drugs for a minimum period of 6 months. In certain cases, MDR-TB patients can take as many as 20 tablets per day for 24 months and only half of these extreme cases achieve stable cure. This significant pill burden leads to higher rates of non-compliance, sub-optimal exposure of the combination components, lower treatment success rates and higher risk of development of further drug resistance.
The current proposal intends to identify and preclinically characterize drug combinations for MDR-TB treatment that could be co-formulated in a single tablet. These fixed-dose combinations (FDCs) would simplify treatment, reduce pill burden, and facilitate patient adherence, increasing efficacy and reducing the risk of resistance development. We will design and formulate FDC products with different vehicles and characterize them with respect to physicochemical properties and in vitro drug release kinetics in a biorelevant system. Succesfull FDCs will be tested in vivo. 

Profile

  • Profile: PhD in Pharmaceutical Sciences.
  • Research experience: PhD thesis work and/or experience in formulation and drug delivery projects, physico-chemical characterization, drug release testing.
  • Communication skills: Ability to work both independently and in a team, direct communication style. Fluency in spoken and written English is mandatory!

Offer

The project is funded by a VLAIO grant. It covers competitive salary, lab and conference expenses.

Interested?

For more information please contact Prof. dr. Guy Van den Mooter, tel.: +32 16 33 03 04, mail: guy.vandenmooter@kuleuven.be.

KU Leuven strives for an inclusive, respectful and socially safe environment. We embrace diversity among individuals and groups as an asset. Open dialogue and differences in perspective are essential for an ambitious research and educational environment. In our commitment to equal opportunity, we recognize the consequences of historical inequalities. We do not accept any form of discrimination based on, but not limited to, gender identity and expression, sexual orientation, age, ethnic or national background, skin colour, religious and philosophical diversity, neurodivergence, employment disability, health, or socioeconomic status. For questions about accessibility or support offered, we are happy to assist you at this email address.

Informatie over de vacature

Functienaam
Postdoctoral project: Design, formulation and evaluation of fixed dose combinations of anti-tuberculosis pharmacotherapy
Werkgever
Locatie
Oude Markt 13 Leuven, België
Gepubliceerd
2024-05-16
Uiterste sollicitatiedatum
2024-06-14 23:59 (Europe/Brussels)
2024-06-14 23:59 (CET)
Soort functie
Baan opslaan

Meer vacatures bij deze werkgever

Over de werkgever

KU Leuven is an autonomous university. It was founded in 1425. It was born of and has grown within the Catholic tradition.

De pagina van de werkgever bekijken